MedTrace Logo

Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions

NCT04607850 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2025-08-28

No results posted yet for this study

Summary

A Phase 1b/2 multi-centre study evaluating the safety, efficacy and immunogenicity of prime-boost vaccines ChAdOx1-HPV and MVA-HPV in women with HPV related low grade cervical lesions.

Conditions

Interventions

BIOLOGICAL

ChAdOx1-HPV

Trial vaccine

BIOLOGICAL

MVA-HPV

Trial vaccine

BIOLOGICAL

Placebo

Saline placebo vaccine

Sponsors & Collaborators

  • Barinthus Biotherapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-16
Primary Completion
2024-01-16
Completion
2024-01-16

Countries

  • Belgium
  • Estonia
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04607850 on ClinicalTrials.gov